Opendata, web and dolomites

AURORAX SIGNED

Advancing cancer detection through metabolism-based diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AURORAX project word cloud

Explore the words cloud of the AURORAX project. It provides you a very rough idea of what is the project "AURORAX" about.

basis    introduce    urologists    ups    renal    surgery    drop    too    platform    stages    niche    significantly    20    surveil    radiation    frequent    independent    imaging    receive    pharmaceutical    detected    oncologist    risks    diagnosed    outcomes    off    treatment    rates    quantification    enter    stage    biopsy    aur87    12    cell    ing    scalable    exceptional    easily    liquid    patients    former    indications    diagnostics    survival    solid    competition    optimize    starting    trials    blood    regulatory    detect    sweden    benefit    companies    rcc    expressing    financially    metastatic    recurrence    trial    algorithmic    aurorax    terminal    200b    improves    launch    patient    recurrences    generate    disease    small    annual    139    cancer    business    elypta    laboratories    first    strategy    letter    monitoring    signature    letters    clinical    regular    perform    follow    demonstrated    validation    clearance    risk    metabolism    sensitivity    carcinoma    frequency    obtain    effectiveness    metabolite    sales    ruo    limited    multiple    signed    urine    market    once   

Project "AURORAX" data sheet

The following table provides information about the project.

Coordinator
ELYPTA AB 

Organization address
address: REGERINGSGATAN 65, 3TR
city: STOCKHOLM
postcode: 111 56
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 3˙346˙674 €
 EC max contribution 2˙342˙671 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELYPTA AB SE (STOCKHOLM) coordinator 2˙342˙671.00

Map

 Project objective

Former cancer patients receive regular follow-ups to detect recurrences at early stages and optimize treatment outcomes. The follow-up frequency is currently limited by costs and radiation risks of imaging approaches used to surveil for recurrences, resulting in recurrences being detected too late – often resulting in terminal disease. Of the 139.000 annual Renal Cell Carcinoma (RCC) patients, 20% are diagnosed with a metastatic recurrence within 5 years after surgery. Once metastatic, RCC survival rates drop to 12% over 5 years survival. Elypta, Sweden, has developed the first metabolism-based liquid biopsy to detect early-stage recurrences. The quantification of a metabolite signature in blood or urine and an algorithmic analysis allows for exceptional sensitivity, a low cost of the platform and significantly improves on imaging approaches in cost and risk, enabling frequent patient follow-up. Elypta’s technology has been demonstrated in small clinical trials and its cost effectiveness assessed by two independent companies. Elypta’s platform is easily scalable to other cancer indications and applications such as treatment monitoring, as demonstrated in multiple small trials. Starting in the niche RCC market with limited competition, Elypta now requires clinical evidence for a product launch within RCC. The business strategy focuses on distribution and sales through clinical laboratories, which will benefit financially off sales. During the AURORAX, Elypta will 1) perform a clinical validation trial (AUR87) to generate strong clinical evidence, 2) obtain regulatory clearance in the EU and the US and 3) introduce the product for research use only (RUO) and after clinical validation enter the RCC diagnostics market in EU. As users of the platform, oncologist and urologists have all signed letters of support. A pharmaceutical partner has also signed a letter of support, expressing their interest in RUO use of the platform, providing a solid basis in the emerging liquid biopsy market (€200B market).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURORAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURORAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More